Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 6, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Tempus AI
- Interventions being studied
- Other: Observation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Solid or hematologic malignancy. 2. Willing and able to provide informed consent where required. 3. Has received or will receive genomic profiling.
1. Individuals without the capacity to consent. 2. Prisoners at the time of enrollment.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UT SouthwesternDallas, Texas
- Baylor College of MedicineHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 6, 2025. Always confirm current availability with the study team.